Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose.
Ontology highlight
ABSTRACT: CD19 CAR-T cells have led to durable remissions in patients with refractory B-cell malignancies; nevertheless, most patients eventually relapse in the long term. Many interventions aimed at improving current products have been reported, with a subset of them focusing on a direct or indirect link to the metabolic state of the CAR-T cells. We assessed clinical products from an ongoing clinical trial utilizing CD19-28z CAR-T cells from patients with acute lymphoblastic leukemia. CAR-T clinical products leading to a complete response had significantly higher mitochondrial function (by oxygen consumption rate) irrespective of mitochondrial content. Next, we replaced the carbon source of the media from glucose to galactose to impact cellular metabolism. Galactose-containing media increased mitoc
SUBMITTER: Gross G
PROVIDER: S-EPMC10557609 | biostudies-literature | 2023 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA